RAMKUMAR MANDALAM, PH.D.

Corporate Board Profile

Tech Score: 13/100

← Back to All Directors

Software Technology Evidence

1 mention(s) identify RAMKUMAR MANDALAM, PH.D. as having software/technology expertise.

Company Filing Date Evidence Reason
Cryoport, Inc. 2014-07-25 Mr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, Michigan. Mr. Mandalam is the author or co-author of several publications, patent applications, and abstracts. Holds a Ph.D. in Chemical Engineering and has extensive experience in biotechnology product development, indicating technical expertise likely including programming or related skills.

Cryoport, Inc.

Filing Date Source Excerpt
2014-07-25 Mr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, Michigan. Mr. Mandalam is the author or co-author of several publications, patent applications, and abstracts.
2015-10-01 Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, Michigan.
2019-04-03 Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan. His background is in biotechnology and management of cell-based therapies.
2020-04-03 Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, Michigan.
2021-03-16 Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, Michigan. Dr. Mandalam’s training as a scientist, extensive background in biotechnology and management expertise and makes him well-qualified to serve as a member of the board of directors.
2022-03-18 Dr. Mandalam has a Ph.D. in Chemical Engineering and extensive biotechnology experience but no mention of programming or software engineering skills.
2023-03-31 Dr. Mandalam is currently the Founder and CEO of Citra BioConsulting Inc., a cell therapy and biologics development consulting firm. Prior to founding Citra BioConsulting in 2021, he was the CEO, President and board member of Cellerant Therapeutics, Inc., a clinical stage biotechnology company developing novel cell-based and antibody therapies for cancer treatment and blood-related disorders. Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, Michigan.
2024-04-03 Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, Michigan. He has extensive background in biotechnology and management expertise.

Data sourced from SEC filings. Last updated: 2026-02-03